The standing of Harrow among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments ...

B. Riley analyst Mayank Mamtani lowered the firm’s price target on Harrow (HROW) to $65 from $69 and keeps a Buy rating on the shares following ...

Appreciate all the comments, guys. Operator: The next question is from the line of Mayank Mamtani with B. Riley Securities. Please proceed with your questions. Mayank Mamtani: Yes, good morning team.

You can hold me to that one, Mayank. On the debt side, Mayank, you know, the plan right now is to enter into some sort of refinancing arrangement with either our partners at Oaktree or some other ...

Good morning and welcome to PDS Biotech's 4th quarter in full year 2024 earnings conference call. Thank you, operator. Good morning, everyone, and welcome to PDS Biotech's 2024 results and ...

At this time, I would now like to turn the conference over to Tom Johnson of LifeSci Advisors. Please go ahead, sir. Thank you, operator. Good morning, everyone. And welcome to PDS Biotech's 2024 ...

PDS Biotechnology Corp (PDSB) reported a net loss of $37.6 million for 2024, an improvement from the $42.9 million loss in 2023, during its Q4 2024 earnings call. The company’s efforts to reduce ...

B. Riley analyst Mayank Mamtani lowered the firm’s price target on Vaxart (VXRT) to $2 from $2.50 and keeps a Buy rating on the shares. The Q4 update reaffirmed the mid-2025 top-line data ...

Lobular carcinoma (LC) presents unique diagnostic challenges due to its subtle imaging characteristics and asymptomatic presentation, often leading to delays in diagnosis and treatment. This ...

We'll begin with the sell side and then take questions from recent conferences. Operator: [Operator Instructions] Our first question comes from the line of Mayank Mamtani with B. Riley Securities.